Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
99.81%
Operating Margin
88.09%
Net Margin
6.70%
Efficiency Metrics
Revenue per Expense Ratio
8.21
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
9.66%
Income Tax Rate
6.60%
EPS
4.0600000000
Balance Sheet Analysis
Current Ratio
0.65
Cash Ratio
0.29
Working Capital
$-6.47B
Debt to Equity
0.29
Debt to Assets
5.37%
Equity Ratio
18.58%
Cash Flow Analysis
Operating Cash Flow Ratio
22.35%
Free Cash Flow Ratio
21.80%
CapEx to Revenue
0.55%
Dividends Paid
$184.03M
Stock Buybacks
$23.60M
Total Shareholder Returns
$207.62M
Cash Position Change
17.82%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 2.13%
Detailed Growth Metrics
Core Performance
Revenue
9.38%
Net Income
68.68%
EPS
78.85%
Operating Income
1,253.26%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
0.60%
Operating Cash Flow
81.38%
Free Cash Flow
91.58%
Balance Sheet Health
Assets
9.62%
Debt
1.76%
Book Value per Share
13.06%
Inventory
100.00%
Shareholder Returns
Dividends per Share
2.13%
Shares Outstanding
0.33%
Long Term Trends
3Y Revenue/Share
14.81%
5Y Revenue/Share
8.22%
3Y Dividend/Share
5.02%
5Y Dividend/Share
2.47%